FY2024 EPS Forecast for Cytosorbents Decreased by Analyst

Cytosorbents Co. (NASDAQ:CTSO) – Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Cytosorbents in a research note issued on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the medical research company will earn ($0.30) per share for the year, down from their prior estimate of ($0.29). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. During the same period in the prior year, the firm posted ($0.14) EPS.

Several other brokerages have also weighed in on CTSO. StockNews.com initiated coverage on shares of Cytosorbents in a report on Sunday, November 10th. They set a “hold” rating on the stock. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Trading Down 5.8 %

Shares of CTSO stock opened at $0.90 on Thursday. The firm has a market cap of $48.94 million, a P/E ratio of -2.49 and a beta of 0.56. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.71. The firm’s 50-day simple moving average is $1.12 and its 200-day simple moving average is $1.01.

Institutional Trading of Cytosorbents

Several large investors have recently bought and sold shares of CTSO. Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the third quarter valued at approximately $51,000. CM Management LLC grew its position in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares in the last quarter. Sargent Investment Group LLC grew its position in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Finally, Avenir Corp grew its position in Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after acquiring an additional 121,294 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.